Access to the PPM Journal and newsletters is FREE for clinicians.
Signup for PPM

All Migraine Articles

In this video Q&A, neurologist and headache expert Lawrence Robbins, MD, and patient advocate Jaime Sanders answer common patient questions on migraine treatments, self-care strategies, anxiety and depression as part of migraine disease, coping during COVID, and more.
Most experts agree that neuroimaging should be used sparingly and with caution when diagnosing and treating migraine. Yet, when to use and when not to use neuroimaging has long been a vexed issue. It’s not always clear when the risks of neuroimaging are justified.
On Saturday, June 13, the American Headache Society (AHS) launched its annual scientific meeting, focused on headache medicine in the era of COVID and frontiers in headache research.
While chronic headache disorders such as cluster headache and migraine are common, they are also largely underestimated and difficult to treat. Many patients experience a poor response to pharmacologic treatment because of inadequate analgesia, intolerable side effects, or the development of drug tolerance.1
The prevalence of migraine in children increases with age and may affect up to 23% of children by age 15, which highlights a need for adequate treatment in these populations.
The prevalence of chronic migraine (CM) is estimated to be about 1.4% to 2.2% worldwide.1 Several preventive treatments are available for patients afflicted with this condition, including sodium valproate, topiramate, and propranolol.
Clinicians have long noted the connection between migraine and obesity. “Most neurologists have seen enough studies that show the link between obesity and migraine,” shared Sylvia Lucas, MD, PhD, clinical professor of neurology, specializing in headaches, at the University of Washington School of Medicine in Seattle.
Early clinical experience with a number of CGRP inhibitors for the prevention of migraine, including Aimovig, Emgality, and Ajovy.
In terms of treating migraine, a recent animal study explored how males and females may respond differently to calcitonin gene-related peptide (CGRP).
The need for a refractory chronic migraine scale for adults and adolescents.
Photobiomodulation and sphenopalatine ganglion blocks are reviewed as migraine alternative treatments. Learn more about light therapy's effectiveness for migraine.
Older adults of both sexes may be at higher risk.
A retrospective review of the author's early clinical experience with the CGRP inhibitor erenumab (Aimovig) for the prevention of migraine.
A look at the differences in risk, presentation, and care of migraine between men and women.
Clinicians can help to answer tough questions about homeschooling and school absences when a child is living with a chronic painful condition.
Biohaven has received FDA authorization to dose first subject with BHV-3500, a new third-generation CGRP.
Many biological factors, including sex hormones, have been reported as a major contributor to migraine.
Biohaven, Lilly, and Allergan's new research from the American Headache Society (AHS) meeting.
Headache expert Lawrence Robbins, MD, asks a series of questions clinicians need to address before prescribing the long-awaited CGRP antagonists for migraine prevention.
In this exclusive roundtable, developers recap the data on their CGRP inhibitors, including Aimovig, the first-ever monoclonal antibodies specifically designed to prevent chronic or episodic migraine.
In  this exclusive roundtable, Amgen/Novartis, Allergan, Lilly, and Teva recap the data that is moving their CGRP migraine preventives to the finish line. Introduction to CGRPs by Lawrence Robbins, MD
Men with chronic migraine have been shown to be at a high risk of sleep apnea and other disorders.
Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018
CGRP receptor antagonists have been well tolerated in studies.
Findings challenge a 2006 FDA advisory, questioning its validity
Lilly survey results point to need for new headache and migraine treatments as well as patient education.
Device from Cefaly Technology promises to abort migraines more effectively than triptans.
A patient’s perception of stress appears to offer a good forecast factor to predict the onset of episodic migraines.
Two studies published in the New England Journal of Medicine report favorable results when targeting calcitonin gene-related peptide with mAb treatments for migraine pain.
A new study demonstrated that dermal application of zolmitriptan may provide significant relief from headache pain and most bothersome migraine symptoms.
For patients with migraines, defining the migraine will ensure proper selection of the medications and complementary therapies based on individual needs to address comorbidities and patient preferences.
Headache expert Duren Michael Ready, MD, provides tips on what to try when nothing else is working.
Case presentation of a chronic migraine patient in her mid-20's. Learn step-by-step treatment plan.
Up to 4% of adults suffer from chronic headaches, mostly migraines. Dr. Lawrence Robbins reviews what we know about migraine types, comorbidities, as well as migraine triggers, and treatments.
Patients with refractory chronic migraine (RCM) experience a great deal of disability related to their chronic headaches.
Migraine headaches are a common cause of disability in the United States, affecting approximately 60 million American adults, or 17.1% of women and 5.6% of men.1 To help define migraines better, the term classical migraine has been replaced with migraine with aura, and nonclassical migraine now is referred to as migraine without aura.
Review will highlight the current definitions of migraines as well as treatment options. Written by a migraine expert; includes review of current migraine medications.
A wide variety of complementary and alternative medicine (CAM) therapies exist for the treatment of migraine, including pharmacologic supplements, physical therapies, medicinal herbs and teas, and relaxation techniques. Should you be using these CAM therapies for migraine patients?
The use of topical treatment modalities for migraine and/or tension-type headaches holds the promise of providing a safe alternative or adjunct to systemic medications. Such treatment also may reduce narcotic dependence and the incidence of rebound headaches.
What do you do when your patient does not do well on their current migraine medications? An Ask the Expert question answered by Dr. John Claude Krusz.
Read about this case: Heather is a 30-year-old hairdresser in a salon. Her work can be very physical, and her life has not been easy. Heather is currently on 50 mg of topiramate and 25 mg of quetiapine to prevent headaches but cannot tolerate higher doses of either medication.
The number one drug used by neurologists for migraine and daily headache, topirimate, is still reluctantly used by primary care physicians. This article is an attempt to demystify a very effective medication in the physician's migraine armentarium.
Article provides an overview of treatment-resistant Migraines. Alternate strategies may be required for overcoming the treatment resistance of certain types of migraines.
Discussion of triptan options in the treatment of migraines. Reviews available migraine medications.
An overview of the efficacy of several triptan agents in menstrually-related migraine (MM), as well as of other treatment modalities that are commonly used in the treatment of MM.
Memantine has only recently been introduced in the U.S. for dementing disorders, although it has been used in Europe for some time. It blocks N-methyl-D-aspartate (NMDA) glutamate receptors that are thought to be intrinsic to pain transmission, windup, long-term potentiation and central sensitization.
Our patient Heather (not her real name) initially came in at age 24 and we chronicled her history and early treatment.1 In summary, Heather has moderate daily headache (CDH), with migraine 6 times per month. She also suffers from anxiety and depression (the mild end of the bipolar spectrum). Heather has irritable bowel syndrome (IBS; primarily diarrhea) plus neck pain.
By affecting chaotic (nonlinear) controls, new therapies may be employed that use less drug in the migraine cascade than is currently required.
For many patients, refractory chronic migraines can be disabling and debilitating. Treating these patients may require a combination of therapeutic approaches.
With a higher than normal prevalence of moderate or severe personality disorder in patients who have migraines, recognizing the disorder allows alteration of both goals and approach.
This retrospective case series study revealed that Hackett-Hemwall dextrose prolotherapy appears to provide an effective, long-lasting treatment for recurring tension and migraine headache pain and their associated symptoms.
Study results for a group of difficult-to-treat migraineurs provide a basis for determining efficacy and guidelines for the use of long-term opioids in this population.
Stimulants may be beneficial for chronic migraine patients presenting with various comorbidities such as attention deficit hyperactivity disorder (ADHD), depression and fatigue.
An outpatient clinic can provide an effective variety of IV treatments—individually or in combination— for definitive control of pain for a variety of pain disorders, including migraines and fibromyalgia.
Outpatient intravenous ketamine treatment of CRPS-Type 1 simultaneously eradicated post-concussional migraine in patient.
A step by step guide through the diagnosis of a complex headache patient. How to diagnosis a chronic migraine patient.
close X